300 related articles for article (PubMed ID: 21824072)
61. Eosinophilic Lung Diseases.
Cottin V
Clin Chest Med; 2016 Sep; 37(3):535-56. PubMed ID: 27514599
[TBL] [Abstract][Full Text] [Related]
62. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
Straumann A; Conus S; Grzonka P; Kita H; Kephart G; Bussmann C; Beglinger C; Smith DA; Patel J; Byrne M; Simon HU
Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
[TBL] [Abstract][Full Text] [Related]
63. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
64. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Varricchi G; Bagnasco D; Ferrando M; Puggioni F; Passalacqua G; Canonica GW
Ther Adv Respir Dis; 2017 Jan; 11(1):40-45. PubMed ID: 27856823
[TBL] [Abstract][Full Text] [Related]
65. Churg-Strauss syndrome.
Greco A; Rizzo MI; De Virgilio A; Gallo A; Fusconi M; Ruoppolo G; Altissimi G; De Vincentiis M
Autoimmun Rev; 2015 Apr; 14(4):341-8. PubMed ID: 25500434
[TBL] [Abstract][Full Text] [Related]
66. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
Castro M; Mathur S; Hargreave F; Boulet LP; Xie F; Young J; Wilkins HJ; Henkel T; Nair P;
Am J Respir Crit Care Med; 2011 Nov; 184(10):1125-32. PubMed ID: 21852542
[TBL] [Abstract][Full Text] [Related]
67. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.
Schmid-Grendelmeier P; Altznauer F; Fischer B; Bizer C; Straumann A; Menz G; Blaser K; Wüthrich B; Simon HU
J Immunol; 2002 Jul; 169(2):1021-7. PubMed ID: 12097410
[TBL] [Abstract][Full Text] [Related]
68. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
69. Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.
Giannetti MP; Cardet JC
Curr Allergy Asthma Rep; 2016 Nov; 16(11):80. PubMed ID: 27796795
[TBL] [Abstract][Full Text] [Related]
70. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome.
Rosenwasser LJ; Rothenberg ME
J Allergy Clin Immunol; 2010 Jun; 125(6):1245-6. PubMed ID: 20513522
[No Abstract] [Full Text] [Related]
71. Benralizumab in the management of rare primary eosinophilic lung diseases.
Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
[No Abstract] [Full Text] [Related]
72. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
73. Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.
Conus S; Straumann A; Simon HU
J Allergy Clin Immunol; 2009 Jan; 123(1):269; author reply 269-70. PubMed ID: 18951621
[No Abstract] [Full Text] [Related]
74. The role of interleukin 5 in asthma.
Varricchi G; Canonica GW
Expert Rev Clin Immunol; 2016 Sep; 12(9):903-5. PubMed ID: 27450970
[No Abstract] [Full Text] [Related]
75. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
76. Eosinophilic Lung Disease.
Weissler JC
Am J Med Sci; 2017 Oct; 354(4):339-349. PubMed ID: 29078837
[TBL] [Abstract][Full Text] [Related]
77. Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence.
Caminati M; Micheletto C; Norelli F; Olivieri B; Ottaviano G; Padoan R; Piacentini G; Schiappoli M; Senna G; Menzella F
Expert Opin Biol Ther; 2024; 24(1-2):15-23. PubMed ID: 38197326
[TBL] [Abstract][Full Text] [Related]
78. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung. A review.
Katzenstein AL
Am J Clin Pathol; 2000 Nov; 114(5):767-72. PubMed ID: 11068552
[TBL] [Abstract][Full Text] [Related]
79. IL-5 expression and release from human CD34 cells in vitro; ex vivo evidence from cases of asthma and Churg-Strauss syndrome.
Bossios A; Sjöstrand M; Dahlborn AK; Samitas K; Malmhäll C; Gaga M; Lötvall J
Allergy; 2010 Jul; 65(7):831-9. PubMed ID: 19968630
[TBL] [Abstract][Full Text] [Related]
80. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.
To M; Kono Y; Yamawaki S; Soeda S; Katsube O; Kishi H; To Y
J Allergy Clin Immunol Pract; 2018; 6(5):1746-1748.e1. PubMed ID: 30201098
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
